Skip to main content
Signal8
Launch Terminal
Fawell Stephen profile photo

Stephen Fawell

CIK: 0002033387

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

C4 Therapeutics, Inc. logo
CCCC

C4 Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • C4 Therapeutics, Inc. logo
    CCCC

    C4 Therapeutics, Inc.

    Jun 24, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    62K shares-
  • C4 Therapeutics, Inc. logo
    CCCC

    C4 Therapeutics, Inc.

    Jun 18, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    35.5K shares-
  • C4 Therapeutics, Inc. logo
    CCCC

    C4 Therapeutics, Inc.

    Aug 29, 2024
    Award(A)

    Stock Option (Right to Buy)

    Direct
    65K shares-

1-3 of 3

About Fawell Stephen

Fawell Stephen (SEC CIK 0002033387) files insider reports with the SEC as Director of C4 Therapeutics, Inc. (CCCC).

Signal8 holds 4 ownership filings by Fawell Stephen (1 Form 3, 3 Form 4), filed between Sep 3, 2024 and Jun 26, 2026. Those filings report 3 transactions, from Aug 29, 2024 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Fawell Stephen's filings is in WATERTOWN, MA.

Recent filings by Fawell Stephen

  • Jun 24, 2026: Grant or award of CCCC derivative securities (Form 4, code A).
  • Jun 18, 2025: Grant or award of CCCC derivative securities (Form 4, code A).
  • Aug 29, 2024: Grant or award of CCCC derivative securities (Form 4, code A).

Other insiders filing for C4 Therapeutics, Inc. (CCCC)

How to read Form 4 transaction codes